SQUIRE Efectos adversos
Neci + Gem-Cis (N=538)
% of patients
Gem-Cis (N=541)
% of patients
Event category
a
Any Grade
Grade ≥3
Any Grade Grade ≥3
Neutropenia
43.7
24.3
45.8
27.5
Febrile neutropenia
1.1
0.7
1.5
1.3
Anemia
41.8
10.6
45.8
10.9
Thrombocytopenia
21.7
10.2
27.0
10.7
Fatigue
42.6
7.2
42.5
7.0
Hypomagnesemia
31.2
9.3
15.7
1.1
Skin rash
76.2
7.1
10.2
0.4
Hypersensitivity/infusion-related reaction
1.5
0.4
2.0
0
Conjunctivitis
7.4
0.4
2.2
0
Interstitial lung disease (pneumonitis)
0.9
0.4
b
0.7
0.6
b
Arterial thromboembolic events
5.4
3.9
c
3.9
2.0
c
Venous thromboembolic events
9.1
5.0
d
5.4
2.6
d
a
Adverse events grouped by medical concept, selected according to treatment relevance
b
Includes 1 fatal event of pneumonitis (0.2%)
c
Fatal arterial thromboembolic events, n (%): Neci + Gem-Cis 3 (0.6%), Gem-Cis 1 (0.2%)
d
Fatal venous thromboembolic events, n (%): Neci + Gem-Cis 1 (0.2%), Gem-Cis 1 (0.2%)
Thatcher N et al. Presented at ASCO 2014. Abstract 8008^
